PULSE NEWS WIRE
Clear, Actionable Intelligence
17,800+
Articles
4,436
Companies
2,300+
Exclusive to PNW
<2 min
To English

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure from Takeda Pharmaceutical Company Limited was processed by Pulse News Wire on March 30, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

Takeda Pharmaceutical Company Takeda Announces Positive Phase 3 Trial Results for Zasocitinib

TOKYO, Mar 30 (Pulse News Wire) – Takeda Pharmaceutical Company Limited (4502.T) announced positive phase 3 clinical trial results for its TYK2 inhibitor, zasocitinib, showing significant improvements

View all Takeda Pharmaceutical Company Limited disclosures →

Know a colleague who covers Japanese equities? Forward them this article — they get 5 free translations to start.

Share on X Share on LinkedIn